Scientific Resources
Posters
- AACR 2025 – Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates
- AACR 2025 – Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insights
- AACR 2025 – The novel PDC AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage
- Affimer® Drug Conjugates (AffDC) targeting Fibroblast Activation Protein-α deliver highly toxic warheads to the tumor microenvironment by leveraging the pre|CISION® release mechanism
- AVA6103, a novel Topoisomerase I FAP-enabled pre|CISION® medicine targeted to the tumor microenvironment via FAP cleavage
- A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate (PDC) in patients with FAP-positive solid tumors
- A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
- Affimer® biotherapeutics: Next generation platform for cancer therapies
- AVA3996, a novel pre|CISION™ medicine, targets a warhead to the tumor microenvironment via Fibroblast Activation Protein (“FAP”) mediated cleavage to elicit tumor cell kill
- A novel, tumor-targeted immunocytokine comprising an anti-PD-L1 Affimer® fused to IL-15 exhibits potent anti-tumor activity
- Affimer® proteins: A novel therapeutic platform
- AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein-alpha (FAP-a) mediated cleavage
- AVA6000, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via FAP mediated cleavage
- Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1
- Half-life Extension Formatting of Human PD-L1 Antagonist Therapeutic Affimers
- Affimer® reagents facilitate affinity chromatography purification of IgG
- See more
Published Papers
- RAS-inhibiting biologics identify and probe druggable pockets including an SII-?3 allosteric site
- Affimer-enzyme-inhibitor switch sensor for rapid wash-free assays of multimeric proteins
- Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics
- Selective Affimers Recognize BCL-2 Family Proteins Through Non-Canonical Structural Motifs
- See more